| ［1］ |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209–249.
|
| ［2］ |
Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer[J]. N Engl J Med, 2022, 386(25): 2363–2376.
|
| ［3］ |
方伟超, 王晨, 刘馨然, 等. 通过构建胃癌类器官共培养模型探究嵌合抗原受体T细胞治疗与临床病理的关系[J/OL]. 中华普通外科学文献(电子版), 2026, 20(2): 89–95.
|
| ［4］ |
Qi C, Liu C, Peng Z, et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician’s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): A randomised, open-label, phase 2 trial[J]. Lancet, 2025, 405(10494): 2049–2060.
|
| ［5］ |
Cheng Z, Wei R, Ma Q, et al. In vivo expansion and antitumor activity of coinfused CD28-and 4–1BB-engineered CAR-T cells in patients with B cell leukemia[J]. Mol Ther, 2018, 26(4): 976–985.
|
| ［6］ |
Xiao X, Huang S, Chen S, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies[J]. J Exp Clin Cancer Res, 2021, 40(1): 367.
|
| ［7］ |
Qi C, Liu C, Gong J, et al. Claudin18. 2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results[J]. Nat Med, 2024, 30(8): 2224–2234.
|
| ［8］ |
Zhang Z, Su M, Jiang P, et al. Unlocking apoptotic pathways: overcoming tumor resistance in CAR‐T‐cell therapy[J]. Cancer Med, 2024, 13(19): e70283.
|
| ［9］ |
Zhu C, Wei Y, Wei X. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications[J]. Mol Cancer, 2019, 18(1): 153.
|
| ［10］ |
Yang S, Ta YN, Chen Y. Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities[J]. Drug Deliv Transl Res, 2025, 15(11): 4067–4097.
|
| ［11］ |
Zhang T, Somasundaram R, Berencsi K, et al. Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4[J]. Eur J Immunol, 2006, 36(2): 457–467.
|
| ［12］ |
Akhurst RJ. Targeting TGF-β signaling for therapeutic gain[J]. Cold Spring Harb Perspect Biol, 2017, 9(10): a022301.
|
| ［13］ |
Leone RD, Powell JD. Fueling the revolution: targeting metabolism to enhance immunotherapy[J]. Cancer Immunol Res, 2021, 9(3): 255–260.
|
| ［14］ |
Zhang J, Dong H, Liang L, et al. Targeting gut microbiota and arginase boosts MEK inhibitors’ enhancement of antitumour immunity via MHC-Ⅰupregulation in colorectal cancer[J]. Br J Cancer, 2025, 133(6): 809–822.
|
| ［15］ |
Sun Y, Wang H, Cui Z, et al. Lactylation in cancer progression and drug resistance[J]. Drug Resist Updat, 2025, 81: 101248.
|
| ［16］ |
Liu X, Ding Q, Zhang H, et al. The CD39-CD73-adenosine axis: master regulator of immune evasion and therapeutic target in pancreatic ductal adenocarcinoma[J]. Biochim Biophys Acta Rev Cancer, 2025, 1880(5): 189443.
|
| ［17］ |
Nair R, Somasundaram V, Kuriakose A, et al. Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies[J]. Front Immunol, 2025, 16: 1548234.
|
| ［18］ |
Long AH, Haso WM, Shern JF, et al. 4–1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors[J]. Nat Med, 2015, 21(6): 581–590.
|
| ［19］ |
孟涛, 曾祥岳, 金博. 靶向 HER2 和 CLDN18. 2 的并联嵌合抗原受体T细胞降低对胃癌的脱靶效应[J]. 安徽医科大学学报, 2022, 57(10): 1595–1601.
|
| ［20］ |
Roybal KT, Rupp LJ, Morsut L, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits[J]. Cell, 2016, 164(4): 770–779.
|
| ［21］ |
Vincent RL, Gurbatri CR, Li F, et al. Probiotic-guided CAR-T cells for solid tumor targeting[J]. Science, 2023, 382(6667): 211–218.
|
| ［22］ |
Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia[J]. N Engl J Med, 2016, 374(4): 311–322.
|
| ［23］ |
Li F, Zhao S, Wei C, et al. Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors[J]. Front Immunol, 2022, 13: 958082.
|
| ［24］ |
Zhou JT, Liu JH, Song TT, et al. EGLIF-CAR-T cells secreting PD-1 blocking antibodies significantly mediate the elimination of gastric cancer[J]. Cancer Manag Res, 2020, 12: 8893–8902.
|
| ［25］ |
Caruana I, Savoldo B, Hoyos V, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes[J]. Nat Med, 2015, 21(5): 524–529.
|
| ［26］ |
Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer[J]. Gut, 2013, 62(1): 112–120.
|
| ［27］ |
Wang Y, Wang J, Yang X, et al. Chemokine receptor CCR2b enhanced anti-tumor function of chimeric antigen receptor T cells targeting mesothelin in a non-small-cell lung carcinoma model[J]. Front Immunol, 2021, 12: 628906.
|
| ［28］ |
Hu W, Li F, Liang Y, et al. Glut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors[J]. J Immunother Cancer, 2025, 13(1): e010540.
|
| ［29］ |
Zhao R, He B, Huang L, et al. Targeting AQP5-mediated arginine deprivation in gastric cancer stem cells restores NK cell anti-tumor immunity[J]. Cell Rep Med, 2025, 6(9): 102333.
|
| ［30］ |
Yang Y, Zhu L, Xu Y, et al. The progress and prospects of targeting the adenosine pathway in cancer immunotherapy[J]. Biomark Res, 2025, 13(1): 75.
|
| ［31］ |
Wang P, Ding W, Mo J, et al. A novel adenosine 2A receptor antagonist HZ-086 enhances the efficiency of immunotherapy and alleviates the acquired resistance to PD-L1 by restoration of T cell functions[J]. Eur J Pharmacol, 2025, 997: 177535.
|
| ［32］ |
Chen X, Yang S, Li S, et al. Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy[J]. Mol Ther Oncolytics, 2021, 21: 144–157.
|
| ［33］ |
Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-engineered T cells in patients with refractory cancer[J]. Science, 2020, 367(6481): eaba7365.
|
| ［34］ |
Zhao Z, Condomines M, van der Stegen SJC, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells[J]. Cancer cell, 2015, 28(4): 415–428.
|
| ［35］ |
Kawalekar OU, O’Connor RS, Fraietta JA, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells[J]. Immunity, 2016, 44(2): 380–390.
|
| ［36］ |
Arcangeli S, Bove C, Mezzanotte C, et al. CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome[J]. J Clin Invest, 2022, 132(12): e150807.
|